The Pulmonary Hypertension Association (PHA) has published a guide to educate healthcare providers and parents on persistent pulmonary hypertension of the newborn (PPHN). The goal, the PHA said, is to help identify the disease right away, so as to start early treatment to prevent complications for the baby.
News
VeriSIM Life has opened PulmoSIM Therapeutics, its pharmaceutical subsidiary focused on developing treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), before moving to other rare respiratory diseases. “We are thrilled to announce the launch of PulmoSIM as it demonstrates the indefinite capabilities of the VeriSIM’s…
Experts will discuss how the COVID-19 pandemic has affected people living with pulmonary hypertension and other rare respiratory diseases during a live panel discussion this week. The event, taking place on Tuesday, March 23, at 7 p.m. CET (2 p.m. EST), is being put on by the European…
Acute pulmonary hypertension (aPH) is frequent and linked with a higher risk of mortality in people who are severely ill with COVID-19, according to a Swedish study. The study, “Acute pulmonary hypertension and short-term outcomes in severe Covid-19 patients needing intensive care,” was published in the journal…
Women who reach menopause prematurely — meaning before age 40 — are two times more likely to develop pulmonary hypertension (PH) than those who do not, a study found. Analysis of medical records covering over 150,000 women registered in the U.K. Biobank also showed that this risk was not associated…
Although pregnancy should be avoided by women with severe pulmonary hypertension (PH), close monitoring by a multidisciplinary team may make it possible in those with moderate PH, a study from China suggests. The study “Long-term outcomes of pregnant women with pulmonary hypertension diagnosed by echocardiography: a…
Pulmonary hypertension (PH) occurs in 60% of children with the heart defect known as patent ductus arteriosus, with girls being more likely to develop PH than boys, a study found. A child with patent ductus arteriosus has an opening, or duct, between two major blood vessels leading from the…
Intravenous use of Uptravi (selexipag) is safe and well-tolerated by pulmonary arterial hypertension (PAH) patients temporarily unable to take this therapy as an oral tablet, a trial found. Patients reported mild side effects from the switch, with the most frequent being common to both oral and intravenous delivery of Uptravi. The…
Many diseases have their own awareness color — breast cancer is pink, muscular dystrophy is green, and AIDS is red, for example — but what’s the significance of pink, green, blue, and purple lights side-by-side? These are the colors most often used to represent Rare Disease Day. This…
A six-month exercise training program can significantly improve physical and psychological well-being in patients with pulmonary hypertension (PH), according to results of a new trial. The study, “Long-Term Effect of an Exercise Training Program on Physical Functioning and Quality of Life in Pulmonary Hypertension: A Randomized Controlled Trial,”…
Despite having lower respiratory muscle strength, people with pulmonary arterial hypertension (PAH) can still use dry powder inhalers that require breath-actuated force to effectively deliver inhaled therapies, a study has found. The study, “Impact of human behavior on inspiratory flow profiles in patients with pulmonary arterial…
The Pulmonary Hypertension Association (PHA) has published a guide that aims to help people recently diagnosed with pulmonary hypertension (PH), as well as their family and caregivers, in better managing the chronic lung disease. The 60-page book, titled “Navigating Pulmonary Hypertension: A Guide for Newly Diagnosed Patients,” covers…
